Here it is: a new article on ctDNA in lymphoma Is a New Era Dawning for ctDNA in Lymphoma? bloodcancerstoday.com//post/is-a-new…

To conclude, the effect of DLBCL cell of origin on polatuzumab efficacy was established by prior studies, & confirmed by 2 RCTs. Should this now inform precision medicine in DLBCL? 12/EOT. #lymsm Lymphoma Research Foundation The Leukemia & Lymphoma Society Lymphoma Hub Andrew M. Evens, DO, MBA, MSc David Russler-Germain, MD/PhD Matthew J. Maurer, ScD Mark Roschewski

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL Mark Roschewski National Cancer Institute Society of Hematologic Oncology (SOHO) #SOHO2023 #hematology ow.ly/IzH550PIYOK

#ctDNA may soon be effectively used to improve upon imaging scans to detect active large cell lymphoma at the end of treatment. #SOHO23 #lymsm | Mark Roschewski National Cancer Institute READ MORE: ow.ly/aOTW50PIX0m

Recommended reading: REVIEW ARTICLES Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy Daniel Hodson Mark Roschewski Haematologica #SCNSL Early View | Haematologica haematologica.org/article/view/h…

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today nature. #lymsm 1/15 nature.com/articles/s4158… PDF link at bottom of this thread

"Mark Roschewski and his colleagues at the NCI speculated that a determination of MRD via ...PhasED-seq could provide a more reliable and complementary method for identifying the lymphoma patients that don't need further salvage therapy." #ASH23 GenomeWeb t.ly/bKQ2_

BTK is known for its role in BCR signaling & BTKi transformed the therapy of lymphoid malignancies. But why do BTKi cause fungal disease? We show that BTK drives neutrophil antifungal activity via p40phox and RAC2 activation; GMCSF rescues BTKi PMN defects jci.org/articles/view/…

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma | New England Journal of Medicine nejm.org/doi/full/10.10… Concept by Wyndham Wilson, pre-clinical rationale by Lou Staudt, and study led by Christopher Melani . Thanks to all patients.

hmpgloballearningnetwork.com/site/onc/confe…

New work from the Lymphoid Malignancies Branch shows that loss of Ga13 drives B cell lymphomas preferentially in the mesenteric lymph nodes. Ga13 is required to counteract mTORC1 and Myc signaling that is driven by the availability of dietary glutamine. rdcu.be/dORlh

Work from the Lymphoid Malignancies Branch reveals that ARID1A and SWI/SNF activity are required for IRF4-dependent transcription. Inhibition of SWI/SNF blocks plasma cell development and is toxic to myeloma cells.sciencedirect.com/science/articl…

Please join me for @KarmanosCancerInstitute’s Sixth Annual Lymphoma Symposium on Aug. 3 at Detroit Marriott Troy. I will be presenting on Primary CNS Lymphoma. Register online by Aug. 1 by visiting karmanos.org/lymphomasympos…

ViPOR regimen in MCL #ASH24 Christopher Melani: - 36 pts (16 R/R), 32% TP53mut, med LOT 3 - R2PD ven dose 400 mg, no TLS, 89% completed all 6 cycles - CR 100% (!!!) - 2-yr PFS: 1L 95%; R/R 75%; 2-yr TTP 100% in TP53mut Also uMRD in 97%! Looking forward to more details on TP53mut. #lymsm

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity | PNAS pnas.org/doi/10.1073/pn… Read the background story of how the VIPOR drugs were discovered to have synergy in LBCL.

"Step-down" trials have historically been more successful than "step-up" trials. We likely do not need 6 cycles for low-risk LBCL. Kudos to investigators

Great news! I predict the tip of the iceberg for these tests. foresight-dx.com/press_releases…

The National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment. Mark Roschewski Ash Alizadeh, MD/PhD 🇺🇸 Stanford Cancer Institute #lymsm #hematology onclive.com/view/ctdna-tes…

Helpful review on ctDNA in lymphoma from Mark Roschewski et al just out in JAMA Oncology David Russler-Germain, MD/PhD Ash Alizadeh, MD/PhD 🇺🇸 #lymsm #lymphoma Hua-Jay (Jeff) Cherng JAMA JAMA Network

#ESHLYMPHOID2025 REGISTRATION AND ABSTRACT SUBMISSION ARE OPEN ➡ bit.ly/4cTSoce Oct 2-4, 2025 in Estoril, Portugal 🇵🇹 8th Translational Research Conference LYMPHOID MALIGNANCIES Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt, Catherine Wu #ESHCONFERENCES